Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is an uncontrolled proliferation of lymphoblasts, which are immature white blood cells. The lymphoblasts, which are produced in the bone marrow, cause damage and death by inhibiting the production of normal cells. Approximately 6,000 patients are diagnosed with ALL in the United States each year, and although just over half of the new diagnoses are in adult patients, the vast majority of the approximately 1,400 deaths per year occur in adults. There are two main types of ALL, B cell ALL and T cell ALL. Approximately 80% of cases of ALL are B cell ALL, which we aim to address with our CD19 product candidates.
Non-Hodgkin’s Lymphomas (NHL)
Non-Hodgkin lymphoma (NHL) is not a single disease, but rather a group of several closely related cancers with different patterns of treatment. Over 70,000 cases of NHL are diagnosed in the U.S. each year. NHL is typically divided into aggressive (fast-growing) and indolent (slow-growing) subtypes. Juno is planning to evaluate multiple product candidates in Phase 1 trials for common types of relapsed or refractory (R/R) B cell NHL of both aggressive and indolent subtypes.
Diffuse Large B cell Lymphoma (DLBCL)
Diffuse large B cell lymphoma (DLBCL) is a fast-growing, aggressive form of NHL. DLBCL comprises approximately 35% of new cases annually, making it the most common type of B cell NHL. Patients with relapsed DLBCL have a poor prognosis with a median survival of ≤12 months for patients who are able to undergo autologous HSCT.
Acute Myeloid Leukemia (AML)
Every year about 13,000 people are diagnosed with AML in the United States, with the incidence increasing in the advanced age group. AML is often incurable with standard systemic therapy. However, despite the many advances in the field of hematopoietic cell transplant (HCT), relapse after transplantation continues to be a major problem, particularly in patients entering HCT with high risk/poor prognosis diseases.
Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia, or CLL, is the most common type of leukemia and it occurs most frequently in older individuals. Each year, approximately 21,000 patients in the United States are diagnosed with CLL. Median progression-free survival in high-risk groups is under 18 to 30 months after frontline therapy, and less than 12 months in multiple-relapsed or refractory disease.